A Study of Merestinib (LY2801653) in Healthy Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 31, 2016

Primary Completion Date

August 31, 2016

Study Completion Date

August 31, 2016

Conditions

Healthy

Interventions

DRUG

Merestinib

Administered orally

Trial Locations (1)

Covance Clinical Research Inc, Daytona Beach

All Listed Sponsors

lead

Eli Lilly and Company

INDUSTRY

NCT02779738 - A Study of Merestinib (LY2801653) in Healthy Participants | Biotech Hunter | Biotech Hunter